Cargando…
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administ...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Endocrine Society
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384669/ https://www.ncbi.nlm.nih.gov/pubmed/25827453 http://dx.doi.org/10.3803/EnM.2015.30.1.19 |